IL-36/IL-36R Signaling Promotes CD4+ T Cell-Dependent Colitis via Pro-Inflammatory Cytokine Production

Abstract

Inflammatory bowel disease (IBD) is a multifactorial, chronic disease that affects approximately 1.5 million people in the United States [1]. It presents with inflammation of the intestine with unknown etiology and its two main forms are Crohns disease (CD) and ulcerative colitis (UC). Several important factors are implicated in the pathogenesis of IBD, one being dysregulation of the immune system resulting in the accumulation and stimulation of innate and adaptive immune cells and subsequent release of soluble factors, including pro-inflammatory cytokines. One of these cytokines is a member of the IL-36 cytokine family, IL-36{gamma}, which is overexpressed in human IBD and experimental mouse models of colitis. In this study, we explored the role of IL-36{gamma} in promoting CD4+ T cell activation and cytokine secretion. We found that IL-36{gamma} stimulation of naive CD4+ T cells significantly induced IFN{gamma} expression in vitro and was associated with augmented intestinal inflammation in vivo using naive CD4+ cell transfer model of colitis. Using IFN{gamma}-/- CD4+ cells, we observed a dramatic decrease in the ability of TNF production and delayed colitis. This data not only suggests that IL-36{gamma} is a master regulator of a pro-inflammatory cytokine network involving IFN{gamma} and TNF, but also highlights the importance of targeting IL-36{gamma} and IFN{gamma} as therapeutic approaches. Our studies have broad implications in relation to targeting specific cytokines in human IBD.